Gastritis
Drug research and approvals for gastritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 34 studies of gastritis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 34
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Validating a Medical AI Fine-Tuning Platform for Major DiseasesNCT07795645 · Not reported · Beijing Friendship Hospital · starts Nov 1, 2024
- The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric…NCT07770126 · Not reported · Universiteit Antwerpen · starts Feb 24, 2025
- A Prospective Cohort Study on Endoscopic Features of Upper Gastrointestinal Tract at High Altitude (Zaduo County)NCT07755384 · Not reported · Jilin University · starts Dec 1, 2025
- Association Between Microplastic Exposure and the Pathological Progression of Gastric CarcinogenesisNCT07542652 · Not reported · Yongquan Shi · starts Mar 31, 2026
- Natural History, Evolution, and Clinical Features of Autoimmune Atrophic GastritisNCT07388459 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Nov 17, 2023
- Distribution Characteristics of Helicobacter PyloriNCT07253948 · Not reported · Jilin University · starts Oct 22, 2025
- Correlation Study of Atrophic Gastritis and Dyspepsia SymptomsNCT07250308 · Not reported · The Third Affiliated hospital of Zhejiang Chinese Medical University · starts Oct 1, 2025
- Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper EndoscopyNCT07245095 · Phase 2 · Hospital General de Mexicali · starts Sep 12, 2025
- Efficacy of Carminal in Helicobacter Pylori GastritisNCT07179237 · Phase 2 · Catalysis SL · starts Aug 4, 2025
Phase 3 7
- Rebamipide
- LansoprazolePotassium-transporting ATPase inhibitor
- EsomeprazolePotassium-transporting ATPase inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- AbeprazanPotassium-transporting ATPase inhibitor
- Recoflavone
Phase 2 1
- OmeprazolePotassium-transporting ATPase inhibitor
Phase 1 or earlier 4
- NizatidineHistamine H2 receptor antagonist
- LafutidineHistamine H2 receptor antagonist
- MosaprideSerotonin 3 (5-HT3) receptor antagonist
- Irsogladine
How its trials ended
200 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 24 whose ending is known, 67% met their primary endpoint, 0% missed it and 33% stopped early.
- Completed, result not reported8141%
- Status unknown4824%
- Ongoing4724%
- Met its primary endpoint168%
- Stopped: enrollment or feasibility42%
- Stopped: other or unclear32%
- Stopped: lack of efficacy11%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Mar 10, 2023 | A phase 2/3, randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic gastritis with or…Dupixent | Regeneron | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA